Scholarlink

Background <p>To investigate the safety and efficacy of transcatheter left atrial appendage occlusion (LAAO) in patients with concomitant atrial fibrillation (AF) and cerebral amyloid angiopathy (CAA) and high bleeding risk that precludes long-term oral anticoagulation.</p> Methods <p>Consecutive patients with non-valvular AF and a CHA2DS2-VASc score ≥ 2 and concomitant CAA who underwent transcatheter LAAO between 2014 and 2022 at Parma University Hospital were included in the analysis. The primary endpoint was a composite of any ischemic/hemorrhagic events. The observed rates of ischemic and bleeding events were compared with those expected from the CHA<sub>2</sub>DS<sub>2</sub>-VASc score and HAS-BLED score.</p> Results <p>Twenty-four patients with probable CAA (median age 74.0 years; 66.7% males) qualified for inclusion. During follow up (median time 17 months), 2 ischemic strokes and 2 ICHs occurred. The rate of primary endpoint event was 8.34/100 patients-year compared to an expected rate of 13.80/100 patients-year, resulting in a 39.6% risk reduction. The risk reduction for systemic thromboembolism and major bleeding was respectively 55.2% and 7.3%.</p> Conclusions <p>Transcatheter LAAO might be an effective strategy for thromboembolic prevention in patients with AF and concomitant CAA. Because of the potential shortcomings, this study can only be considered as hypothesis-generating.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Atrial fibrillation and coexisting cerebral amyloid angiopathy: safety and efficacy of transcatheter left atrial appendage occlusion

  • 期刊论文

  • 发表日期：

    2026年4月23日

查看全文
  • Filippo Luca Gurgoglione,
  • Federico Barocelli,
  • Emilia Solinas,
  • Giorgio Benatti,
  • Maria Alberta Cattabiani,
  • Iacopo Tadonio,
  • Angela Guidorossi,
  • Giovanna Pelà,
  • Stefano Coli,
  • Daniele Sartorio,
  • Giampaolo Niccoli,
  • Alessandro Pezzini,
  • Luigi Vignali

摘要

Background

To investigate the safety and efficacy of transcatheter left atrial appendage occlusion (LAAO) in patients with concomitant atrial fibrillation (AF) and cerebral amyloid angiopathy (CAA) and high bleeding risk that precludes long-term oral anticoagulation.

Methods

Consecutive patients with non-valvular AF and a CHA2DS2-VASc score ≥ 2 and concomitant CAA who underwent transcatheter LAAO between 2014 and 2022 at Parma University Hospital were included in the analysis. The primary endpoint was a composite of any ischemic/hemorrhagic events. The observed rates of ischemic and bleeding events were compared with those expected from the CHA2DS2-VASc score and HAS-BLED score.

Results

Twenty-four patients with probable CAA (median age 74.0 years; 66.7% males) qualified for inclusion. During follow up (median time 17 months), 2 ischemic strokes and 2 ICHs occurred. The rate of primary endpoint event was 8.34/100 patients-year compared to an expected rate of 13.80/100 patients-year, resulting in a 39.6% risk reduction. The risk reduction for systemic thromboembolism and major bleeding was respectively 55.2% and 7.3%.

Conclusions

Transcatheter LAAO might be an effective strategy for thromboembolic prevention in patients with AF and concomitant CAA. Because of the potential shortcomings, this study can only be considered as hypothesis-generating.